Skip to content
Screener

Mirum Pharmaceuticals, Inc. MIRM Other operating expenses

Other operating expenses at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$215M+33.1%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$6.23M+167%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$27.18M-8.9%
LifeMD, Inc. logo
LifeMD, Inc.LFMD
$53.17M+21.0%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
0%0.0pp

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Operating income-$42.5M-753%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.45B+144%
Enterprise value$6.2B+151%
P/S10.4×+4.3×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development90,52846,067188,43887,111
Acquired in-process research and development16,435742,7375,000
Selling, general and administrative81,46963,286177,799120,992
Total operating expenses218,780132,7741,168,127259,542
Loss from operations(42,537)(4,989)(832,002)(20,172)
Other income (expense):
Interest income3,8513,0337,2526,056
Interest expense(2,618)(3,589)(6,234)(7,185)

Item 1. Financial Statements (Unaudited)

FAQ

What is Mirum Pharmaceuticals, Inc.'s other operating expenses?
Mirum Pharmaceuticals, Inc. (MIRM) reported other operating expenses of $218.78M in Q2 2026.
How has Mirum Pharmaceuticals, Inc.'s other operating expenses changed year-over-year?
Mirum Pharmaceuticals, Inc.'s other operating expenses increased by 64.8% year-over-year, from $132.77M to $218.78M.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s other operating expenses?
Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s other operating expenses has grown at a 29.6% compound annual growth rate (CAGR), from $192.55M to $543.45M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.

Ask your AI about Mirum Pharmaceuticals, Inc.'s other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude